HighTower Advisors’s Anixa Biosciences ANIX Stock Holding History

HighTower Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Sell	41,150 -400	-1%	-$1.11K	﹤0.01%	3641
2026 Q1	$107K	Buy	41,550 +400	+1%	+$1.18K	﹤0.01%	3628
2025 Q4	$128K	Hold	41,150	–	–	﹤0.01%	3468
2025 Q3	$136K	Buy	41,150 +3,000	+8%	+$9.49K	﹤0.01%	3480
2025 Q2	$126K	Buy	38,150 +25,000	+190%	+$71.4K	﹤0.01%	3421
2025 Q1	$37.6K	Sell	13,150 -73	-0.6%	-$209	﹤0.01%	3475
2024 Q4	$30.7K	Sell	13,223 -300	-2%	-$932	﹤0.01%	3503
2024 Q3	$43K	Sell	13,523 -500	-4%	-$1.54K	﹤0.01%	3426
2024 Q2	$31K	Buy	14,023 +500	+4%	+$1.42K	﹤0.01%	3362
2024 Q1	$42K	Hold	13,523	–	–	﹤0.01%	3275
2023 Q4	$52K	Buy	+13,523	New	+$45.6K	﹤0.01%	3299

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

HighTower Advisors's ANIX Position: Q2 2026 in Review

HighTower Advisors reduced its Anixa Biosciences (ANIX) stake by 0.96% in Q2 2026, selling an estimated $1.11K and leaving 41,150 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

HighTower Advisors first reported a position in ANIX in Q4 2023 and has held it in 11 quarters since. The position peaked at $136K in Q3 2025. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

HighTower Advisors held 41,150 shares of Anixa Biosciences worth $115K as of Q2 2026.
HighTower Advisors sold 400 Anixa Biosciences shares in Q2 2026, an estimated $1.11K.
Anixa Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3641 holding.
HighTower Advisors first reported a position in Anixa Biosciences in Q4 2023 and has held it in 11 quarters since.
HighTower Advisors's Anixa Biosciences position peaked at $136K in Q3 2025.
62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.